Moderna’s Shift to Cancer Company Lifts Stock Up 177%
The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.
Full story
Read the full story at The New York Times - Business ↗
Continue reading this story on The New York Times - Business, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.